Century Therapeutics, Inc. expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026. Mr. Truitt, currently CEO of iECURE, Inc., will serve on the Compensation Committee and receive an initial option grant for 148,000 shares vesting over 36 months plus an annual cash retainer of $40,000. The appointment supports leadership as the company advances its iPSC-derived cell therapy pipeline toward key milestones in 2026. Century Therapeutics is a biotechnology company developing induced pluripotent stem cell-derived therapies for autoimmune diseases and cancer.
